20/20 BioLabs, Inc. (Nasdaq: AIDX) will host an investor webinar on October 7, 2026, at 12:00 p.m. Eastern time. Jonathan Cohen, President and Chief Executive Officer, will discuss the September 23 meeting of the U.S. Food and Drug Administration (FDA), the U.S. medical-products regulator, Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee and its favorable vote on the safety, effectiveness and overall benefit-risk profile of GRAIL’s Galleri® multi-cancer early detection (MCED) blood test for adults aged 50 and older. Cohen will outline what management believes the panel’s deliberations may indicate for the broader MCED category and for 20/20 BioLabs’ regulatory and reimbursement strategy for OneTest™ for Cancer, including the statutory Medicare pathway for FDA-authorized MCED blood tests beginning in 2028 and the company’s goal of obtaining Medicare reimbursement for MCED by the end of 2028. The company will also discuss its new OneTest™ franchise model, preliminary interest from laboratories across the United States and new state funding initiatives for firefighter cancer screening. Under the model, independent regional laboratories would offer OneTest™ in defined territories and verticals, while 20/20 BioLabs retains ownership of its machine-learning models, patented methods and longitudinal biomarker data. The company says the approach could support broader expansion without building a national sales force. The event will include a live question-and-answer session, advance questions may be sent to AIDX@mzgroup.us, and a replay will be posted on the company’s investor relations website. Attendees will receive a promotional discount code for OneTest™, regardless of shareholder status. The webinar is not expected to include material non-public information.